Novel Investigational Diabetes Drug Significantly Lowers Blood Sugar Levels

EMBARGOED FOR RELEASE: 6:00 PM, 6/14/98

**MEDIA ALERT**

NOVEL INVESTIGATIONAL DIABETES DRUG SIGNIFICANTLY LOWERS BLOOD SUGAR LEVELS

Data Show That SmithKline Beecham's Rosiglitazone Directly Targets an Underlying Cause of Type 2 Diabetes

WHAT: Presentations of Phase III Clinical Data and Pre-clinical Studies at ADA

-- "Rosiglitazone Monotherapy Has Significant Glucose Lowering Effect in Type 2 Diabetic Patients," Sunday, June 14 (8:30 am - 8:45 am) McCormick Place, Room E451

-- "Rosiglitazone Increases Pancreatic Islet Area, Density and Insulin Content, but not Insulin Gene Expression," Sunday, June 14 (9:45 am - 10:00 am) McCormick Place, Room E451

-- "The PPAR-gamma Agonist Rosiglitazone, Reverses Hyperinsulinemia and Promotes Growth of Islet Beta-cell Mass," Monday, June 15 (5:00 pm - 5:15 pm) McCormick Place, Room N426

WHO: Diabetes Experts and Investigators Available for Interview:
-- James Gavin, MD, past ADA president and senior scientific officer, Howard Hughes Medical Institute, Chevy Chase, MD
-- Barry Goldstein, MD, director, Division of Endocrinology, Diabetes and Metabolic Diseases, Department of Medicine, Jefferson Medical College, Philadelphia, PA
-- Doug Greene, MD, chief, Division of Endocrinology and Metabolism, University of Michigan School of Medicine and director, Michigan Diabetes Research and Training Center, Ann Arbor, MI
-- Harold Lebovitz, MD, professor of medicine, chief, Endocrinology and Metabolism/Diabetes and director, Diabetes, Diagnostic and Training Center, State University of New York Health Science Center in Brooklyn.

WHEN: American Diabetes Association Annual Meeting, McCormick Place,

2301 South Lake Shore Drive, Chicago, June 13 - 16, 1998

CONTACT: Lisa Richardson at 312/329-7659 or Susan Bro at 312/329-7654

# # #